3/2
09:04 am
dftx
Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
Definium Therapeutics (DFTX) had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a "buy" rating on the stock.
2/28
03:23 pm
dftx
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]
Low
Report
Definium Therapeutics Weighs Breakthrough Status Against Valuation And Trial Risks [Yahoo! Finance]
2/26
11:40 pm
dftx
Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Definium Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
04:14 pm
dftx
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]
2/26
04:01 pm
dftx
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
Low
Report
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
2/25
06:24 am
dftx
Definium Therapeutics (DFTX) was upgraded by Wolfe Research to "strong-buy".
Low
Report
Definium Therapeutics (DFTX) was upgraded by Wolfe Research to "strong-buy".
2/24
07:21 am
dftx
Definium Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Definium Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]
2/24
07:01 am
dftx
Definium Therapeutics to Participate at Upcoming Investor Conferences
Low
Report
Definium Therapeutics to Participate at Upcoming Investor Conferences
2/23
06:01 pm
dftx
Definium Therapeutics (NASDAQ:DFTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Definium Therapeutics (NASDAQ:DFTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
2/19
04:13 pm
dftx
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Low
Report
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
2/19
04:01 pm
dftx
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
Low
Report
Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026
2/18
09:53 pm
dftx
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III [Yahoo! Finance]
Low
Report
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III [Yahoo! Finance]
2/2
04:00 pm
dftx
Definium Therapeutics Announces New Employee Inducement Grants
Low
Report
Definium Therapeutics Announces New Employee Inducement Grants
2/2
10:57 am
dftx
Definium Therapeutics (NASDAQ:DFTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Definium Therapeutics (NASDAQ:DFTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
2/1
12:32 am
dftx
Roger Adsett Joins Definium As Commercial Focus Meets Trial Milestones [Yahoo! Finance]
Medium
Report
Roger Adsett Joins Definium As Commercial Focus Meets Trial Milestones [Yahoo! Finance]
2/1
12:32 am
dftx
Did Adding Biopharma Veteran Roger Adsett to the Board Just Shift Definium Therapeutics' (DFTX) Investment Narrative? [Yahoo! Finance]
Medium
Report
Did Adding Biopharma Veteran Roger Adsett to the Board Just Shift Definium Therapeutics' (DFTX) Investment Narrative? [Yahoo! Finance]
1/31
07:45 am
dftx
Definium Therapeutics (NASDAQ:DFTX) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Medium
Report
Definium Therapeutics (NASDAQ:DFTX) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
1/29
07:03 pm
dftx
Definium Therapeutics (NASDAQ:DFTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Definium Therapeutics (NASDAQ:DFTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
1/29
10:04 am
dftx
Definium Therapeutics (NASDAQ:DFTX) was given a new $37.00 price target on by analysts at Robert W. Baird.
Low
Report
Definium Therapeutics (NASDAQ:DFTX) was given a new $37.00 price target on by analysts at Robert W. Baird.
1/29
07:00 am
dftx
Definium Therapeutics Appoints Roger Adsett to Board of Directors
Low
Report
Definium Therapeutics Appoints Roger Adsett to Board of Directors
1/26
04:46 pm
dftx
Definium Therapeutics Announces New Employee Inducement Grants [Yahoo! Finance]
Medium
Report
Definium Therapeutics Announces New Employee Inducement Grants [Yahoo! Finance]
1/26
04:01 pm
dftx
Definium Therapeutics Announces New Employee Inducement Grants
Medium
Report
Definium Therapeutics Announces New Employee Inducement Grants
1/23
10:20 am
dftx
Definium Therapeutics (NASDAQ:DFTX) had its price target raised by analysts at Royal Bank Of Canada from $20.00 to $36.00. They now have an "outperform" rating on the stock.
Low
Report
Definium Therapeutics (NASDAQ:DFTX) had its price target raised by analysts at Royal Bank Of Canada from $20.00 to $36.00. They now have an "outperform" rating on the stock.
1/20
07:00 am
dftx
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
High
Report
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care
1/19
08:42 pm
dftx
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns [Yahoo! Finance]
Low
Report
A Look At Definium Therapeutics (DFTX) Valuation After Recent Double Digit Share Price Returns [Yahoo! Finance]